Thiazolidine-2,4-dione Conjugated with Aryl/Benzyl Piperazines: Design, Synthesis, Tyrosinase Inhibitory Activity, and In Vitro and In Vivo Anti-Melanogenic Effects
7 affiliations
- 1Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy
- 2Department of Life and Environmental Sciences, Polytechnic University of Marche, 60131 Ancona, Italy
- 3Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98168 Messina, Italy
- 4Research Core Facilities, Fondazione Istituto di Ricerca Pediatrica Città della Speranza ETS, 35127 Padova, Italy
- 5Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35127 Padova, Italy
- 6Istituto di Ricerca Pediatrica (IRP), Fondazione Città della Speranza, 35128 Padova, Italy
- 7Hemato-Oncology Lab, Department of Woman’s and Child’s Health, University of Padova, 35128 Padova, Italy
Abstract
Tyrosinase is a key enzyme in melanogenesis and a target for the development of agents against hyperpigmentation. In this study, fifteen thiazolidine-2,4-dione derivatives conjugated with aryl- or benzylpiperazine moieties were designed and synthesized using a molecular hybridization strategy. Their inhibitory activity against mushroom tyrosinase was evaluated together with molecular docking, and selected compounds were further tested in SK-MEL-31 human melanoma cells and wild-type AB/TU zebrafish embryos. Ten derivatives inhibited mushroom tyrosinase more potently than kojic acid. Linker length and aromatic substitution strongly influenced activity, with TDP10 and TDP2 showing the highest potency (IC50 = 0.41 and 0.79 μM, respectively). Kinetic studies revealed inhibition profiles consistent with a non-competitive mechanism for both compounds. The selected derivatives reduced α-MSH-induced intracellular tyrosinase activity at 50 μM, with TDP7 producing the greatest effect. In zebrafish embryos, TDP2, TDP7, and TDP10 reduced pigmentation to different extents, with TDP7 showing a marked effect at 100 μM. Developmental toxicity assessment revealed concentration-dependent adverse effects at 100 μM, particularly for TDP10, whereas no adverse endpoints were observed at lower concentrations. These findings identify the thiazolidine-2,4-dione-aryl/benzylpiperazine scaffold as a promising starting point for the development of new tyrosinase inhibitors, while highlighting the importance of further efficacy and safety evaluation.
Related
- Systemic, RPE-directed AAV-tyrosinase therapy restores ocular pigmentation in an OCA1 mouse model
- A Deformulating Multi-Attribute SEC Method for Simultaneous Quantification of Total RNA, Conjugated Antibody, and Free Antibody in Targeted Lipid Nanoparticles
- A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy
- Influence of antibody-antigen interaction on fluorescence of Rhodamine 6G conjugated to the antibodies measured in human serum
- Redox and structural determinants of mitochondrial complex III inhibition by triphenylphosphonium-conjugated atovaquone analogs
BibTeX
@article{romagnoli2026thiazolidine24dione,
title = {{Thiazolidine-2,4-dione Conjugated with Aryl/Benzyl Piperazines: Design, Synthesis, Tyrosinase Inhibitory Activity, and In Vitro and In Vivo Anti-Melanogenic Effects}},
author = {Romeo Romagnoli and Tiziano De Ventura and Elena Romagnoli and Maria Paola Germanò and Salvatore Mirabile and Laura De Luca and Giovanna Pitasi and Diana Corallo and Roberta Bortolozzi and Giampietro Viola},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210204},
url = {https://www.mdpi.com/1422-0067/27/22/10204},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Thiazolidine-2,4-dione Conjugated with Aryl/Benzyl Piperazines: Design, Synthesis, Tyrosinase Inhibitory Activity, and In Vitro and In Vivo Anti-Melanogenic Effects
AU - Romeo Romagnoli
AU - Tiziano De Ventura
AU - Elena Romagnoli
AU - Maria Paola Germanò
AU - Salvatore Mirabile
AU - Laura De Luca
AU - Giovanna Pitasi
AU - Diana Corallo
AU - Roberta Bortolozzi
AU - Giampietro Viola
PY - 2026
DA - 2026/11/13
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210204
UR - https://www.mdpi.com/1422-0067/27/22/10204
AB - Tyrosinase is a key enzyme in melanogenesis and a target for the development of agents against hyperpigmentation. In this study, fifteen thiazolidine-2,4-dione derivatives conjugated with aryl- or benzylpiperazine moieties were designed and synthesized using a molecular hybridization strategy. Their inhibitory activity against mushroom tyrosinase was evaluated together with molecular docking, and selected compounds were further tested in SK-MEL-31 human melanoma cells and wild-type AB/TU zebrafish embryos. Ten derivatives inhibited mushroom tyrosinase more potently than kojic acid. Linker length and aromatic substitution strongly influenced activity, with TDP10 and TDP2 showing the highest potency (IC50 = 0.41 and 0.79 μM, respectively). Kinetic studies revealed inhibition profiles consistent with a non-competitive mechanism for both compounds. The selected derivatives reduced α-MSH-induced intracellular tyrosinase activity at 50 μM, with TDP7 producing the greatest effect. In zebrafish embryos, TDP2, TDP7, and TDP10 reduced pigmentation to different extents, with TDP7 showing a marked effect at 100 μM. Developmental toxicity assessment revealed concentration-dependent adverse effects at 100 μM, particularly for TDP10, whereas no adverse endpoints were observed at lower concentrations. These findings identify the thiazolidine-2,4-dione-aryl/benzylpiperazine scaffold as a promising starting point for the development of new tyrosinase inhibitors, while highlighting the importance of further efficacy and safety evaluation.
SN - 1422-0067
ER -